ACIP issues interim recommendation for Pfizer COVID-19 vaccine in adolescents aged 12-15

The Advisory Committee on Immunization Practices (ACIP) has issued an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12-15 years in the United States for the prevention of COVID-19. This represents a policy recommendation from a national advisory body rather than a report of new clinical trial data.

No specific study details, sample size, comparator group, follow-up duration, or numerical efficacy data are reported in this announcement. The recommendation does not include information about adverse events, serious adverse events, discontinuations, or tolerability in this age group.

Key limitations include the absence of supporting clinical data in this announcement and the interim nature of the recommendation. The funding sources and potential conflicts of interest for this recommendation are not reported. This interim recommendation suggests the vaccine may be appropriate for this population but awaits more complete evidence for full endorsement.